How would you manage adjuvant therapy in a BRCA1-mutated woman with ER+, Her2 negative breast cancer with residual disease at surgery after neoadjuvant therapy with a taxane-based regimen?  

Could carboplatin be considered here? Or any evidence for a PARP inhibitor?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Uniformed Services University of the Health Sciences (USUHS)
Would you offer adjuvant capecitabine if patient h...
Medical Oncologist at Clinical Instructor
To call readers attention, we do have similar ques...
Sign in or Register to read more